Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system that administers high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. The company is also conducting the FOCUS clinical trial to evaluate HEPZATO in patients with metastatic hepatic dominant uveal melanoma, measuring objective response rates. In Europe, Delcath markets the CHEMOSAT Hepatic Delivery System, a stand-alone medical device used for melphalan delivery to treat various liver cancers. The company operates in both the United States and Europe, targeting a significant unmet need in liver cancer treatment.

Delcath Systems, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DCTH. Its shares are traded in U.S. dollars (USD), reflecting its primary listing in the United States. The NasdaqCM is a U.S.-based stock exchange that typically hosts smaller-cap companies, and Delcath's listing there provides liquidity and visibility to investors interested in the healthcare and medical device sectors.

Delcath Systems operates in the Healthcare sector and is classified under the Medical Devices industry. This means the company develops and commercializes medical devices and related therapies, specifically focusing on interventional oncology—a field that uses minimally invasive procedures to treat cancer. Its products, such as the HEPZATO KIT and CHEMOSAT system, are categorized as medical devices that deliver chemotherapy directly to liver tumors, combining device technology with pharmaceutical agents.

Delcath Systems, Inc. is headquartered in Queensbury, New York, United States. The company serves both the U.S. and European markets. In the United States, its lead product candidate HEPZATO KIT is under clinical investigation, while in Europe, the CHEMOSAT Hepatic Delivery System is commercially available for medical centers to treat a range of liver cancers. This dual-market strategy allows Delcath to address liver cancer patients across different regulatory environments.

Delcath Systems generates revenue primarily through the commercialization of its interventional oncology products. In Europe, the company sells the CHEMOSAT Hepatic Delivery System as a stand-alone medical device, which hospitals and clinics purchase to administer melphalan chemotherapy for liver cancer treatments. In the United States, Delcath is pursuing regulatory approval for HEPZATO KIT, and upon approval, it would generate revenue from sales of the combined drug-device product. The company also conducts clinical trials, such as the FOCUS trial, to expand indications and support product adoption. Revenue is derived from product sales and potentially from licensing or partnerships.